Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1961 1
1996 1
2004 1
2005 2
2006 1
2007 6
2008 4
2009 3
2010 1
2011 7
2012 11
2013 14
2014 6
2015 8
2016 8
2017 13
2018 9
2019 15
2020 15
2021 18
2022 15
2023 9
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: ichihara e. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: ichihara e. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: ichihara e. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
[COVID-19 Pneumonia].
Kudo K, Ichihara E. Kudo K, et al. Among authors: ichihara e. Gan To Kagaku Ryoho. 2020 Dec;47(12):1657-1661. Gan To Kagaku Ryoho. 2020. PMID: 33342977 Japanese.
Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E, Miyahara N, Maeda Y, Kiura K. Ichihara E, et al. Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. Epub 2019 Sep 18. Intern Med. 2020. PMID: 31534086 Free PMC article. Review.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, Kiura K. Morita A, et al. Among authors: ichihara e. Int J Cancer. 2024 May 1;154(9):1607-1615. doi: 10.1002/ijc.34842. Epub 2024 Jan 9. Int J Cancer. 2024. PMID: 38196128
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection.
Ichihara E, Hasegawa K, Kudo K, Tanimoto Y, Nouso K, Oda N, Mitsumune S, Yamada H, Takata I, Hagiya H, Mitsuhashi T, Taniguchi A, Toyooka S, Tsukahara K, Aokage T, Tsukahara H, Kiura K, Maeda Y. Ichihara E, et al. PLoS One. 2023 Oct 26;18(10):e0287501. doi: 10.1371/journal.pone.0287501. eCollection 2023. PLoS One. 2023. PMID: 37883347 Free PMC article. Clinical Trial.
158 results